Diabetes-Zentrum-Wilhelmsburg GbR

At Diabetes-Zentrum-Wilhelmsburg GbR in Hamburg, clinical trials in cardiovascular diseases focus on better prevention and treatment of heart-related complications, especially in people with type 2 diabetes, hypertension, and established vascular disease. The research is aimed at evaluating new therapies that may reduce the risk of major cardiovascular events, heart failure, and related outcomes.

• Studies in atherosclerotic cardiovascular disease are assessing new ways to lower LDL cholesterol and improve risk reduction.
• Several trials examine heart failure prevention and outcomes in people with diabetes, high blood pressure, or kidney disease.
• Research also includes treatments designed to lower the chance of major adverse cardiovascular events in high-risk patients.

Overall, this therapeutic area is centered on testing innovative approaches that may improve long-term cardiovascular protection and support better management of complex metabolic risk.

The site is also active in nutritional and metabolic diseases, with a strong emphasis on obesity, overweight, and diabetes. These studies explore new treatment options to improve blood sugar control, support weight loss, and address related conditions such as kidney disease and eye complications.

• Trials in type 1 diabetes and type 2 diabetes are evaluating therapies that may improve glycaemic control and simplify treatment.
• Weight-management studies are testing new medicines for people with obesity or overweight, including those with additional health risks.
• Some research focuses on diabetic retinopathy, aiming to better understand and protect eye health in people with diabetes.
• Other studies look at chronic kidney disease and metabolic complications to improve overall disease control and long-term outcomes.

These trials reflect a broad effort to develop more effective, patient-friendly therapies for metabolic health across diabetes, body weight, and related complication management.